SNA-125

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameSNA-125
Drug Alias NameSNA-125CT-340
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNerve growth factor receptor Trk-A antagonistsTyrosine-protein kinase JAK3 inhibitors
TargetsNerve growth factor receptor Trk-ATyrosine-protein kinase JAK3
Therapy Area/IndicationsPsoriasisPruritusDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCreabilis SaSienna Biopharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSienna Biopharmaceuticals IncCreabilis Sa
Inactive CompaniesN/A
Active IndicationsPsoriasisPruritusDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A